# A comprehensive summary of the GISM annual meeting 2025

**Authors:** Enrico Ragni, Rita Romani, Valentina Grespi, Gabriele Scattini, Giulio Severi, Enrico Lucarelli, Stefano Grolli, Maddalena Mastrogiacomo, Silvia Dotti, Antonietta Rosa Silini, Maurizio Muraca, Filippo Piccinini, Michela Pozzobon, Laura de Girolamo, Ivana Ferrero, Maria Luisa Torre, Augusto Pessina, Luisa Pascucci

PMC · DOI: 10.20517/evcna.2025.61 · Extracellular Vesicles and Circulating Nucleic Acids · 2025-08-14

## TL;DR

Experts discussed recent advances in stem cell and extracellular vesicle research for regenerative medicine and nanomedicine.

## Contribution

The paper highlights novel strategies to improve the therapeutic potential of MSCs and EVs for clinical use.

## Key findings

- Standardizing production methods is crucial for clinical scalability of MSCs and EVs.
- Cell engineering and targeted drug delivery are emerging therapeutic approaches.
- Interdisciplinary collaboration is key to advancing nanomedicine and regenerative therapies.

## Abstract

The GISM Annual Meeting 2025 convened experts in regenerative medicine and nanomedicine to discuss recent advances in mesenchymal stromal/stem cell (MSC) research and extracellular vesicle (EV) technologies. The meeting emphasized novel strategies to enhance the therapeutic potential of MSCs and EVs, addressing both basic biological insights and translational challenges. Discussions highlighted the importance of standardizing production and characterization methods to improve scalability and reproducibility for clinical applications. Emerging therapeutic approaches, including cell engineering and targeted drug delivery, were showcased alongside preclinical and clinical studies. The conference provided a platform for interdisciplinary exchange, fostering collaboration and paving the way toward the clinical integration of EV and cell-based nanomedicine.

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** Musculoskeletal Diseases (MESH:D009140), KCS (MESH:D007638), GISTs (MESH:D046152), liver metastases (MESH:D009362), aneurysmal bone cysts (MESH:D017824), SDH-deficient (MESH:D007153), toxicity (MESH:D064420), dry eyes (MESH:D015352), bone defects (MESH:D001847), Knee Osteoarthritis (MESH:D020370), bronchopulmonary dysplasia (MESH:D001997), hypoxic (MESH:D002534), OA (MESH:D010003), hypoxia (MESH:D000860), liver diseases (MESH:D008107), inflammation (MESH:D007249), pancreatic ductal adenocarcinoma (MESH:D021441), fibrosis (MESH:D005355), pain (MESH:D010146), pancreatic cancer (MESH:D010190), Cancer (MESH:D009369), liver fibrosis (MESH:D008103), lung injury (MESH:D055370)
- **Chemicals:** Afternoon (-), thioacetamide (MESH:D013853), polycaprolactone (MESH:C016240), CFSE (MESH:C087165), alginate (MESH:D000464)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12540258/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12540258/full.md

---
Source: https://tomesphere.com/paper/PMC12540258